Leasing health technologies- an affordable and effective reimbursement strategy for innovative technologies?
The challenge of implementing high cost innovative technologies in health care systems operating under significant budgetary pressure has seen a radical shift in the health technology reimbursement landscape. New reimbursement strategies attempt to reduce the risk of making the wrong decision; i.e. paying for a technology that is not good value for the health care system, whilst promoting the adoption of innovative technologies into clinical practice. However, the remaining risk is not shared between the manufacturer and the health care payer at the individual purchase level; it continues to be passed from the manufacturer to the payer at the time of purchase. In this paper we propose a health technology payment strategy – Technology Leasing Reimbursement Scheme (TLRS) - which allows the sharing of risk between the manufacturer and the payer; the replacing of upfront payments with a stream of payments spread over the expected duration benefit from the technology, subject to the technology delivering the claimed health benefit. Using trastuzumab (Herceptin) in Early Breast Cancer as an exemplar technology we show how a TLRS not only reduces the total budgetary impact of the innovative technology, it also truly shares risk between the manufacturer and the health care system, whilst reducing the value of further research and thus promoting the rapid adoption of innovative technologies into clinical practice.
If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
|Date of creation:||2013|
|Contact details of provider:|| Phone: Worsley Building, Level 11, Clarendon Way, LEEDS LS2 9NL|
Fax: +44 (0) 113 343 3470
Web page: http://medhealth.leeds.ac.uk/auhe
More information through EDIRC
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- McCabe, C & Claxton, K & Culyer, AJ, 2008. "The NICE Cost-Effectiveness Threshold: What it is and What that Means," MPRA Paper 26466, University Library of Munich, Germany.
- Peter Hall & Claire Hulme & Christopher McCabe & Yemi Oluboyede & Jeff Round & David A Cameron, 2010. "Updated cost-effectiveness analysis of trastuzumab for early breast cancer:A UK perspective considering long-term toxicity and pattern of recurrence," Working Papers 1001, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
- Christopher McCabe & Richard Edlin & Peter Hall, 2013.
"Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?,"
Springer, vol. 31(9), pages 731-737, September.
- Christopher McCabe & Richard Edlin & Peter Hall, 2012. "Navigating time and uncertainty in health technology appraisal: would a map help?," Working Papers 1201, Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds.
When requesting a correction, please mention this item's handle: RePEc:lee:wpaper:1302. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Judy Wright)
If references are entirely missing, you can add them using this form.